RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours
The mTOR inhibitor everolimus more than doubled the time to progression in advanced pancreatic neuroendocrine tumours, becoming one of the first two targeted drugs approved for the disease in 2011.
Overview
Phase 3 placebo-controlled trial of 410 patients with advanced, low- or intermediate-grade, progressive pancreatic neuroendocrine tumours randomised to everolimus 10 mg daily or placebo.
Median progression-free survival was 11.0 versus 4.6 months (hazard ratio 0.35), with stomatitis, rash, diarrhoea and hyperglycaemia as the characteristic toxicities; overall survival was similar because of crossover.
- Median progression-free survival 11.0 vs 4.6 months; hazard ratio 0.35.
- Objective response 5 percent; benefit was disease stabilisation.
Everolimus is a standard option for progressive pancreatic neuroendocrine tumours, alongside sunitinib, chemotherapy and radioligand therapy.
- Crossover obscured any survival benefit.
- Hyperglycaemia is a particular concern in this population.
Similar pages
not linked directly; found by shared links- TreatmentDiazoxide
- Key paperSunitinib malate for the treatment of pancreatic neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
- Key paperCLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
- TrialRADIANT-3 and RADIANT-4
- Key paperCABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
- TrialLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
- TrialCOMPETE
- TargetmTOR